Rôle et activités d un Centre Collaborateur de l OMS : le CC- OMS sur les méningites

Similar documents
Serogroup W in Africa & travellers

Surveillance Feedback Bulletin

MENINGITIS EPIDEMIC TRENDS in AFRICA. Mamoudou H. DJINGAREY, MD/MPH WHO-IST/WEST AFRICA OUAGADOUGOU

Content. Introduction. Overview of reported outbreaks in WHO African Region. Disease Surveillance and Response. Vol. 2 Issue 3, April 30, 2012

J. M. COLLARD 1 *, Z. MAMAN 2,A.ABANI 2,H.B.MAINASARA 1,S.DJIBO 1, H. YACOUBA 2,R.MAITOURNAM 2, F. SIDIKOU 1, P. NICOLAS 3, J.

in the meningitis belt

Meningitis Outbreak Response intervention thresholds in sub-saharan Africa

Predicting Meningitis Risk in Africa

Impact of MenAfriVac in nine countries of the African meningitis belt, : an analysis of surveillance data

Stockpile needs for epidemic meningitis response Dr Caroline Trotter

Content. Introduction. Overview of reported outbreaks in WHO African Region. Disease Surveillance and Response. Vol. 2 Issue 4, 26 May 2012

Investigation of a Neisseria meningitidis Serogroup A Case in the Meningitis Belt. January 2017

Report for the WHO Meningitis Guideline Revision (May 2014)

Pre- Travel Case Studies (*with Key Pads)

PREVENTION OF MENINGOCOCCAL MENINGITIS BY VACCINATION IN THE AFRICAN MENINGITIS BELT

MSF Field Research. Biological diagnosis of meningococcal meningitis in the. meningitis belt: current epidemic strategy and new perspectives.

Comments on this bulletin are welcome. Please to Dr. Mary Agócs

The Rise and Fall of Epidemic Neisseria meningitidis Serogroup W135 Meningitis in Burkina Faso,

Outcome of Epidemiological Surveillance of Bacterial Meningitis in Mali from 1996 to 2016: What Lesson to Learn?

Global Burden of Meningococcal Disease. Prof. David Salisbury CB FRCP FRCPCH FFPH FMedSci. Centre for Global Health Security, Chatham House, London.

Yellow fever laboratory capacity on-site assessments in Africa: preliminary findings

World Health Organization Emerging and other Communicable Diseases, Surveillance and Control

Meningitis outbreak response in sub-saharan Africa. WHO guideline

Meningococcal meningitis

The MenAfrivac Experience A Successful Approach. Dr Bernard FRITZELL BFL conseils France

Public health impact of MenAfriVac: the first four years

Update on Meningococcal A Vaccine Development and Introduction

Vol. 5 Issue 2, 31 May 2015

Epidemic meningitis: Surveillance and response activities during the season in the countries of the African meningitis belt

TRANSPARENCY COMMITTEE OPINION. 4 March 2009

Pfizer s Investigational Vaccine, rlp2086, for Invasive Meningococcal Serogroup B Disease

Community outbreak of group B meningococcal disease in southwest France December 2008 to September 2009

Epidemiological patterns of bacterial meningitis in Niger from 2002 to 2010

Serotyping pneumococcal meningitis cases in the African meningitis belt using multiplex. PCR on cerebrospinal fluid

Örebro University Hospital

Sporadic Cases of Meningococcal Meningitis Serogroup W-135 Ethiopia, 2013

Annual Report of the National Center for Meningococci 2005

Downloaded from:

Meningococcal Disease a resurgence of an old foe?

Dust and meningitis. A multidisciplinary work Preliminary results

World Health Organization Emerging and other Communicable Diseases, Surveillance and Control

( A JICA-IRRI-PhilRice Initiative) Presented by Noel Magor, Head Unit Impact Acceleration and Training Center, IRRI

Swiss National Reference Center for Meningococci. > 2015 Annual Report <

Swiss National Reference Center for Meningococci. > 2014 Annual Report <

POLIO ERADICATION IN THE AFRICAN REGION: PROGRESS REPORT. Information document EXECUTIVE SUMMARY

History, implementation and impact of MenA conjugate on disease burden in Africa

Emergence of Epidemic Neisseria meningitidis Serogroup X Meningitis in Togo and Burkina Faso

National Institute for Communicable Diseases -- Weekly Surveillance Report --

Neisseria meningitidis; clones, carriage, and disease

Örebro University Hospital

PUBLIC HEALTH EMERGENCIES AND RESPONSES IN WEST AND CENTRAL AFRICA

Published by Centers for Disease Control (CDC) Archived on this site by permission of CDC, [url]

David L. Suarez D.V.M., PhD. A.C.V.M.

PROGRESS REPORT ON CHILD SURVIVAL: A STRATEGY FOR THE AFRICAN REGION. Information Document CONTENTS

Influenza Surveillance In the WHO African Region

An AW outer membrane vesicle (OMV) meningococcal vaccine trial in Ethiopia. Tesfamariam Mebrahtu Armauer Hansen Research Insitute

Evaluation of the Pastorex meningitis kit for the rapid identification of Neisseria meningitidis serogroups A and W135

Local Public Health Department. Communicable diseases Environmental health Chronic diseases Emergency preparedness Special programs

Regional Consultation on Nutrition and HIV/AIDS in French Speaking Countries in Africa Region

EBOLA SITUATION REPORT

ESCMID Online Lecture Library. by author

Wild Poliovirus*, 03 Aug 2004 to 02 Aug 2005

Current and Emerging Legionella Diagnostics

Received 15 January 2009/Returned for modification 29 April 2009/Accepted 22 June 2009

Yellow fever Vaccine investment strategy

Epidemic Meningococcal Disease and Travel

WHO position paper on meningococcal vaccines

Aboubacar Kampo Chief of Health UNICEF Nigeria

Hans Jürgen Dornbusch

POLIOMYELITIS ERADICATION: PROGRESS REPORT. Information Document CONTENTS BACKGROUND PROGRESS MADE NEXT STEPS... 12

Dr. Valentina Picot Research Advisor. Fondation Mérieux

How to Detect and Confirm Epidemic Meningococcal Disease

CONTENTS. Paragraphs I. BACKGROUND II. PROGRESS REPORT ON THE AFRICAN REGIONAL IMMUNIZATION STRATEGIC PLAN

Increased incidence of invasive meningococcal disease of serogroup C / clonal complex 11, Tuscany, Italy, 2015 to 2016

CDER EDITORIAL Through this issue of the

International Coordinating Group for vaccine provision. Emergency Vaccine Stockpiles

Medical Innovation changing business model. Marie-Paule Kieny, WHO-WIPO-WTO, 5 July 2013

UNAIDS 2013 AIDS by the numbers

Baseline Meningococcal Carriage in Burkina Faso before the Introduction of a Meningococcal Serogroup A Conjugate Vaccine

EBOLA SITUATION REPORT

Laboratories continue to play a critical role in all

ANNEX Page. AFR/RC61/11 4 July 2011 ORIGINAL: ENGLISH REGIONAL COMMITTEE FOR AFRICA

IMMUNIZATION VACCINE DEVELOPMENT

TFI Proceedings, Recommendations and implications for 2005

IMMUNIZATION VACCINE DEVELOPMENT

West and Central Africa

ST2859 serogroup A meningococcal meningitis outbreak in Nouna Health District, Burkina Faso: a prospective study

Status of Outbreak Vulnerable Countries

INVASIVE NEISSERIA MENINGITIDIS IN EUROPE 2002

Bacterial meningitis in adults: Host and pathogen factors, treatment and outcome Heckenberg, S.G.B.

Main conclusions and options for response

SITUATIONAL REPORT. Cluster of Meningococcal Disease in Foya District, Lofa County Liberia. 27th January 2018

Procedure for Expedited Review of imported pre-qualified vaccines for use in national immunization programmes

Reactive vaccination as a control strategy for pneumococcal meningitis outbreaks in the African meningitis belt: analysis of outbreak data from Ghana

Acute Communicable Disease Outbreaks among MSM, 2016

CDC s Commitment to National Laboratory Systems to Achieve Global Health Security

INVASIVE NEISSERIA MENINGITIDIS IN EUROPE 2001

IMMUNIZATION & VACCINE PREVENTABLE DISEASES

Can infant vaccination prevent pneumococcal meningitis outbreaks in sub-saharan Africa?

Implementation of MenACWY vaccination because of ongoing increase in serogroup W invasive meningococcal disease, the Netherlands, 2018

Transcription:

Rôle et activités d un Centre Collaborateur de l OMS : le CC- OMS sur les méningites Muhamed-Kheir Taha MD, PhD Invasive Bacterial Infections CNR des Méningocoques et Haemophilus influenzae WHOcc for meningitis Institut Pasteur Paris 2ème journée CNR LNR 17 Novembre 2017

Current mandate and Terms of Reference Four-years mandate Nov2016-Nov2020 TOR 1 :To support WHO in meningitis outbreak investigation and documentation by providing detailed laboratory confirmation and molecular analysis. TOR 2 : To support WHO in strengthening countries meningitis laboratory diagnostic capacity. Conducted Activities: - Capacity building: Transfer of technologies, teaching and training - Conducting Interlaboratory studies of quality assurance. - Developing new bedside diagnostic tools -Typing of meningococcal isolates - Exploring Vaccine Failure

Diagnosis and typing - Implementation of molecular typing methods for the three agents Nm, Sp and Hi - Development of bedside tests - Molecular typing 2016-2017 n=183 samples (primary samples and isolates)

Typing of Neisseria meningitidis for changing epidemiology Genotyping MLST: polymorphism of several genes. Whole Genome sequencing (WGS) Monitoring population biology Phenotyping Naturally competent for transformation Capsule (12serogroups) A. B. C. W. Y. X 99% of cases E.H. I. J. L. Z Rare among invasive isolates in immunecompetent patients Maiden et al.. 2013 Nat Rev Microbiol. Frequent horizontal DNA exchanges

Teaching and training One-week course from 29 May to 2 June 2017 at the Institut Pasteur Funding: TOTAL Foundation Both theoretical and practical courses Five participants from Cameroon: CAR, Côte d Ivoire, Niger and Morocco Diagnosis and typing of Neisseria meningitidis PCR-based diagnosis both on primary samples and cultured isolates RDT Antibiogram MALDI-TOF WGS bioinformatics training

EQA June 2016 Distribution of 8 samples ( spiked CSF) to participating laboratories Institut Pasteur (Abidjan, Côte d Ivoire) Institut Pasteur (Bangui, CAR) CERMES (Niamey, Niger) Institut Pasteur (Casablanca, Morocco) Laboratory results L14 L15 L17 L18 % species identification consensus 62.5 100 100 87.5 % genogroup identification consensus 50 100 100 83.3

Rapid beside diagnostic tools for Nm Capture control line antibodies Capture line antibodies against NmX Gold-labeled binding antibodies against NmX Sp Sn A 98 (96-99) 91 (77-98) C 100 (99-100) 64 (45-80) Y 100 (99-100) 75 (35-97) W 95 (91-98) 97 (92-98) X 99 (96-100) 100 (89-100) Transfer to an industrial partner for industrial production A kit of three cassettes to detect serogroups A, C, Y, W and X in field testing during 2017-2018 season

Meningococcal Isolates from countries in the African Meningitis Belt 2004-2010 100 % 90 % 80 % 70 % 60 % 50 % 40 % 30 % 20 % 10 % 0 % 100 % 90 % 80 % 70 % 60 % 50 % 40 % 30 % 20 % 10 % 0 % Niger (N=124) Burkina Faso (N=283) Serogroup distribution (%) 2004 2005 2006 2007 2008 2009 2010 2004 2005 2006 2007 2008 2009 2010 Caugant et al.. PLoSONE 2012 100 % 90 % 80 % 70 % 60 % 50 % 40 % 30 % 20 % 10 % 0 % 100 % 90 % 80 % 70 % 60 % 50 % 40 % 30 % 20 % 10 % 0 % Mali (N=132) Chad (N=53) 773 isolates (2004 and 2010) 13 sub-saharan countries A X 2004 2005 2006 2007 2008 2009 2010 2004 2005 2006 2007 2008 2009 2010 W Y

Agents of acute bacterial meningitis sub- Saharan Africa (2014) OMS REH, No. 13, 2015, 90, 121-132

Vaccine failure Molecular analysis of the isolates level of the expression of the capsule and sequence insertion in the promoter cps region Serological analysis of the bactericidal antibodies induced by the vaccine. Complement analysis in patients

Epidemic Neisseria meningitidis Serogroup C: Nigeria and Niger since 2013 Core genomemlst loci-based Neighbour-net phylogenetic network ST-10217 C:P1.21-15,16:F1-7:NA (ST-10217) cc11 cc865 Sidikou et al., 2016 Lancet Infect Dis; Kretz et al., 2015. Emerg Infect Dis

Cameroon 2017 Community-acquired case Meningococcal meningitis epidemic within a prison in Yaoundé 7 isolates and 11 CSF samples W:P1.5,2:F1-1:cc11 (ST-11) C:P1.5-1,2-36:F5-1:cc175 (ST-2881)

NmC Cameroon 2017 in Africa Cameroon cc175 (C) 2017 ST-10217 cc11 cc865

NmX in Africa : Emergence since 2006 WGS cc181 Isolates (Africa) cc181.2 cc181.1 Europe Agnememel et al., Emerg Infect Dis 22, 698 (Apr, 2016).

Undiagnosed illness - Liberia A cluster of sudden deaths of unknown aetiology in Sinoe County Liberia between 23 April and 7 May 2017, a total of 31 cases including 13 deaths. Fever, abdominal pain, diarrhea, vomiting, and mental confusion. Some patients presented with purpura and/ or petechiae. Neisseria meningitidis group C by PCR in clinical specimens (31 cases) and serological results of 3 cases Toxicological investigations were not suggestive of intoxication The importance of the inclusion of meningococcal septicemia in routine surveillance. The Liberian national reference laboratory in Margibi County CDC Atlanta, USA, The National Institute for Communicable Diseases (NICD) and the National Institute of Occupational Health (NIOH) in Johannesburg, South Africa, The Institut Pasteur in Paris, France. Center for Analytical Chemistry in Vienna, Austria,

Changing epidemiology in Sub-Saharan Africa Decline NmA (cc5) Emergence of W (cc11) in 2001-2002 After the decline of serogroup W between 2003 and 2005, a new increase in W is observed since 2010 Outbreaks of group X (cc181) meningococci in Niamey 2007 in Ghana and Togo in 2007-2008 and in Burkina Faso 2010-2011. NmC in Nigeria and Niger since 2013

Ala-Eddine Deghmane Eva Hong Aude Terrade La Plateforme de Microbiologie Mutualisée (P2M) du PIBnet de l Institut Pasteur Xin Wang CCOMS CDC Atlanta USA Dominique Caugant CCOMS NIPH Oslo, Norway Katya Fernandez and Olivier Ronveaux WHO, Geneva Switzerland Centre d enseignement de l Institut Pasteur MRF Fondation TOTAL

Distribution of cc175 isolates (n=370) (+2 Cameroon) (+12 Cameroon)

Cameroon 2017 against NmW in Africa Hajj cc11 (W) South American-UK cc11 (W) Cameroon cc11 (W) Cameroon cc175 (C)

Possible global spread of NmX cc181? Stefanelli et al., Emerg Infect Dis 23, 870 (May, 2017).